Important progress was made in a number of innovative drug r&d in fujian powerful r&d strength

July 12, 2013

Source: xinmin network

        Fuzhou 11 news reporter learned from the provincial department of science, biotechnology and biomedical areas in fujian province invention transfer ownership, ranking sixth in the country, a number of innovative drug research and development made important progress.

        According to understand, research and development of fujian province in China's first capsule type hepatitis b drug resistance en GanDing get production approval; "Key technology of human infection with avian influenza therapeutic antibodies preclinical research" project pilot production out of the group of single drug resistance, won the state food and drug administration clinical registration notice of acceptance; "Tenofovir ester compound and its salt capsule drug preclinical research" project approval documents received three clinical trials; "Cervical cancer cell targeting detection kits" has obtained the certificate of product registration and patent, products will be listed; "Diabetes stem cell treatment key technology research and application" project important progress, diabetic patients with treatment can reduce the dosage of insulin; Xiamen university and YangShengTang wantai company for 14 years, has invested nearly 500 million yuan jointly developed the "recombinant hepatitis e vaccine (e. coli)" won the national first class new drug certificate and production approval document, is the world's first vaccine available to prevent hepatitis; Short c_6d_6 mountain dwarf lilyturf become our province after rhizoma alismatis, radix pseudostellariae third national food and drug administration of traditional Chinese medicine GAP certification.

        At present, the work is carried out by the science of fujian "biomedical project research and development of fujian province incubators construction plan", will build a large instrument platform and biotech drugs platform, to introduce domestic first-class public service outsourcing new drug research and development institutions, to attract and gathered inside enterprises, universities and research institutes of research and development resources and power.

The original link: http://finance.ifeng.com/a/20130712/10147121_0.shtml

(this site editor Wang Zhong one)